Compounds and methods for inhibiting histone demethylases: a patent evaluation of US20160102096A1 [0.03%]
组化合物及抑制组去甲基酶的方法：美国专利申请US20160102096A1的评估
Florian Thaler,Ciro Mercurio
Florian Thaler
The Jumonji C (JmjC) domain containing histone lysine demethylases have a clear role both in the development and in some diseases including inflammation and cancer. The histone lysine demethylases represent an attractive target for the iden...
Jin-Hee Park,Yong-Chul Kim
Jin-Hee Park
The P2X7 receptor (P2X7R) is a unique subtype among the family of seven purinergic P2X receptors, which are ATP-gated non-selective cation channels. P2X7R has been reported to have pathological roles in various diseases, including autoimmun...
Inhibitors of phospholipase A2 and their therapeutic potential: an update on patents (2012-2016) [0.03%]
磷脂酶A2抑制剂及其治疗潜力：2012-2016年专利概况更新
Maroula G Kokotou,Dimitris Limnios,Aikaterini Nikolaou et al.
Maroula G Kokotou et al.
The regulation of the catalytic activity of the various phospholipase A2 enzymes is of high importance because these enzymes are involved in various pathological conditions such as arthritis, cardiovascular diseases, neurological diseases, ...
Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors: a patent evaluation of US20160011199A1 [0.03%]
用于肿瘤靶向成像化合物的氨基酸连接基团的合成与组成：对US20160011199A1专利的评估
Jean-Yves Winum
Jean-Yves Winum
The present patent discloses the identification of small-molecule fluorescent probes constituted by pteroic acid moiety connected to near-infrared (NIR) dye via amino acids. These folate receptor (FR) targeted conjugates were shown to have ...
Substituted indole Mcl-1 inhibitors: a patent evaluation (WO2015148854A1) [0.03%]
麦클-1抑制剂类似物吲哚专利点评（WO2015148854A1）
Ting Song,Ziqian Wang,Zhichao Zhang
Ting Song
The myeloid cell leukemia 1 (Mcl-1) protein, an anti-apoptotic member of Bcl-2 family, plays a critical role in the development and maintenance of many cancers and is listed in the 'top ten' pathological factors across the diversity of huma...
Luca Mologni,Carlo Gambacorti-Passerini,Peter Goekjian et al.
Luca Mologni et al.
Tyrosine kinases are involved in the control of several biological processes and have been recognized as hot spots of oncogenic transformation, thus representing a major therapeutic target. Dysregulated activation of RET kinase, either thro...
Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015) [0.03%]
内质网蛋白激酶(PERK)抑制剂专利回顾(2010-2015)
Jeffrey M Axten
Jeffrey M Axten
PKR-like endoplasmic reticulum kinase (PERK) is an essential component of the unfolded protein response (UPR) and a critical regulator of protein synthesis during endoplasmic reticulum (ER) stress. Transient PERK activation is protective; h...
Therapeutic potential of boswellic acids: a patent review (1990-2015) [0.03%]
没药酸的治疗潜力：一项专利综述(1990-2015)
Hidayat Hussain,Ahmed Al-Harrasi,Rene Csuk et al.
Hidayat Hussain et al.
Boswellic acids (BAs), a group of pentacyclic triterpenoids, have demonstrated very interesting biological properties that resulted in a number of protocols being developed for their synthesis. During the last twenty-five years (1990-2015),...
Sarah M Bronner,Jason R Zbieg,James J Crawford
Sarah M Bronner
The transcription factor RORγ plays a critical role in the expression of pro-inflammatory cytokine interleukin IL-17 and is therefore an attractive target for the treatment of inflammatory diseases. Interest in this molecular target has be...
Tetrahydroisoquinolines in therapeutics: a patent review (2010-2015) [0.03%]
四氢异喹啉类药物的专利回顾(2010-2015)
Inder Pal Singh,Purvi Shah
Inder Pal Singh
1,2,3,4-Tetrahydroisoquinoline (THIQ) is one of the 'privileged scaffolds', commonly found in nature. Initially, this class of compounds was known for its neurotoxicity. Later on, 1-methyl-1,2,3,4-tetrahydroisoquinoline was proved as an end...